Court Sets Aside R15.5 Billion HIV Drug Tender Awards in South Africa
What happened
A court set aside the awards for a R15.5-billion antiretroviral tender managed by the Department of Health. Two winning bidders were excluded because the factory license they relied on had expired before the bidding closed. The Department of Health has been given 120 days to redo the awards, while current suppliers will continue delivering the medicines in the interim. The tender covers critical drugs like Tenofovir, lamivudine, and dolutegravir, which are used by millions of South Africans.
From bizcommunity.com
Why it matters
The ruling forces the Department of Health to restart a major procurement process for essential medicines. The tender, which is one of the largest of its kind, is vital for maintaining the national drug supply chain in South Africa. The court decision also validates the challenge brought by Cipla.
From bizcommunity.com
Who's involved
- CiplaChallenged the tender awards set by the Department of Health.
- Department of HealthManaged the R15.5-billion antiretroviral tender.
- South AfricaThe country where the critical drug tender was awarded.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- South AfricaSpeculative
The procurement failure could threaten the stability of the national drug supply chain in South Africa.
- Department of HealthSpeculative
The court ruling requires the Department of Health to restart the procurement process, potentially increasing administrative costs.
Keep exploring
The entities involved
-
Cipla
Indian multi-national pharmaceutical and biotechnology company
-
Department of Health
department of the Hong Kong Government